GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Univo Pharmaceuticals Ltd (XTAE:UNVO-M) » Definitions » EV-to-Revenue

Univo Pharmaceuticals (XTAE:UNVO-M) EV-to-Revenue : 0.92 (As of Jul. 15, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Univo Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Univo Pharmaceuticals's enterprise value is ₪40.32 Mil. Univo Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 was ₪43.89 Mil. Therefore, Univo Pharmaceuticals's EV-to-Revenue for today is 0.92.

The historical rank and industry rank for Univo Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

XTAE:UNVO-M's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.2
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-07-15), Univo Pharmaceuticals's stock price is ₪930.00. Univo Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was ₪14,631.00. Therefore, Univo Pharmaceuticals's PS Ratio for today is 0.06.


Univo Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Univo Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Univo Pharmaceuticals EV-to-Revenue Chart

Univo Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only - - 73.39 2.59 2.31

Univo Pharmaceuticals Quarterly Data
Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.33 2.66 2.31 1.89 1.47

Competitive Comparison of Univo Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Univo Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Univo Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Univo Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Univo Pharmaceuticals's EV-to-Revenue falls into.


;
;

Univo Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Univo Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=40.322/43.893
=0.92

Univo Pharmaceuticals's current Enterprise Value is ₪40.32 Mil.
Univo Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪43.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Univo Pharmaceuticals  (XTAE:UNVO-M) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Univo Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=930.00/14631
=0.06

Univo Pharmaceuticals's share price for today is ₪930.00.
Univo Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪14,631.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Univo Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Univo Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Univo Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Harshar 20, Ashkelon, ISR, 7878329
Univo Pharmaceuticals Ltd is engaged in designing & developing drugs for the treatment of brain disorders. The company provides cannabis-based products for distribution and export to the international markets.

Univo Pharmaceuticals Headlines

No Headlines